Form 4: Nuvation Bio CFO Sells Shares Under 10b5-1 Plan

Nuvation Bio Inc. CFO Philippe Sauvage sold 47,668 shares of Class A Common Stock for an average price of $6.00, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc., reported a transaction on June 23, 2026.
• Sauvage sold 47,668 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan established on December 4, 2025.
• The weighted-average sale price was $6.00, with individual sales ranging from $6.00 to $6.04.
• Following the sale, Sauvage beneficially owns 12,673 shares of Class A Common Stock.
• Additionally, Sauvage acquired 47,668 shares through the exercise of a stock option at a price of $2.17 per share, with the option expiring on October 6, 2034.
• The stock option vests over time, with 25% vesting on the one-year anniversary of October 7, 2024, and the remainder vesting monthly over the subsequent 36 months, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment. While the transaction is executed under a 10b5-1 plan, which is a standard practice, a significant sale by a CFO can still be interpreted as a bearish signal by the market.

Positives

• The sale was conducted under a pre-established 10b5-1 plan, indicating a planned and orderly divestment rather than a reaction to negative news.
• The stock option exercise at $2.17 and subsequent sale at a higher average price of $6.00 suggests a profitable transaction for the executive.
• The vesting schedule for the remaining stock options indicates continued commitment to the company over the next few years.

Negatives

• The sale of a significant number of shares by the CFO could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The difference between the option exercise price ($2.17) and the sale price ($6.00) represents a gain for the executive, but the market may focus on the outflow of shares.

Risks

• The sale of shares by a key executive could lead to negative investor sentiment and potentially impact the stock price.
• The ongoing vesting of stock options implies that further sales could occur in the future as these options become exercisable.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. However, the vesting schedule of the stock options suggests potential future transactions by the reporting person.

Management Comments

• The sale was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology sector. Executives often utilize 10b5-1 plans to diversify holdings or manage personal finances in a structured manner, which can mitigate concerns about insider trading, though significant sales can still influence market perception.

Stakeholder Impact

• Shareholders: May perceive the CFO's sale as a negative signal, potentially leading to short-term stock price pressure. However, the 10b5-1 plan structure aims to mitigate concerns about insider trading.
• Employees: May view the sale with concern if it suggests a lack of confidence from management, potentially impacting morale.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Next Steps

• Continued vesting of stock options over the next 36 months following October 7, 2024.
• Potential future sales of shares as options vest and are exercised, subject to the 10b5-1 plan or other trading strategies.

Key Dates

Recommendation

The filing details a routine transaction by an executive under a 10b5-1 plan, which is not inherently indicative of a change in the company's fundamental value. While the sale might cause short-term market jitters, the underlying business performance and future prospects, not detailed here, would be the primary drivers for a buy or sell decision. Therefore, a 'hold' recommendation is appropriate pending further information.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, 10b5-1 Plan, Nuvation Bio, NUVB, Philippe Sauvage, Chief Financial Officer, Stock Options, Beneficial Ownership